Blog

Elvina Almuradova: Promising results with Daraxonrasib in RAS-mutant PDAC

Elvina Almuradova/LinkedIn

Jan 28, 2025, 08:26

Elvina Almuradova: Promising results with Daraxonrasib in RAS-mutant PDAC

Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, posted the following on LinkedIn:

“Daraxonrasib (RMC-6236), an investigational pan-RAS inhibitor, shows promising early results in RAS-mutant PDAC, with a 36% response rate in second-line therapy and a median overall survival of 14.5 months. Common toxicities include rash, diarrhea, and nausea, but they are mostly manageable. The phase 3 RASolute trial is ongoing to compare it with standard chemotherapy.

I’m thrilled to have had the opportunity to join the phase 1 trial of this groundbreaking drug at IEO Istituto Europeo di Oncologia.”

cancer chemotherapy alternatives clinical trials DaraxONRASib Elvina Almuradova IEO Istituto Europeo di Oncologia OncoDaily Oncology oncology research Pancreatic Cancer RAS mutation RMC-6236 targeted therapy

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

President Trump has announced U.S. Withdrawal from the World Health Organization

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

The Princess of Wales thanks The Royal Marsden for looking after her during her battle with cancer